CP
LGND icon

Castleview Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Castleview Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,071
Closed -$58K – 685
2022
Q3 		$58K Buy
+1,071
New +$63K 0.06% 236

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Castleview Partners's LGND Position: Q4 2022 in Review

Castleview Partners sold out of Ligand Pharmaceuticals (LGND) in Q4 2022, closing a stake of 1,071 shares — an estimated $58K sold.

Castleview Partners first reported a position in LGND in Q3 2022 and held it in 1 quarter. The position peaked at $58K in Q3 2022. 198 funds tracked by Wall St. Rank hold LGND as of Q4 2022.

  • Castleview Partners reported no remaining Ligand Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Castleview Partners sold 1,071 Ligand Pharmaceuticals shares in Q4 2022, an estimated $58K.
  • Castleview Partners first reported a position in Ligand Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Castleview Partners's Ligand Pharmaceuticals position peaked at $58K in Q3 2022.
  • 198 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2022.

Based on Castleview Partners's 13F filing for Q4 2022, filed 1 Feb 2023.